1. Home
  2. WNEB vs IPHA Comparison

WNEB vs IPHA Comparison

Compare WNEB & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

HOLD

Current Price

$13.86

Market Cap

264.8M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.36

Market Cap

141.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WNEB
IPHA
Founded
1853
1999
Country
United States
France
Employees
N/A
163
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.8M
141.7M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
WNEB
IPHA
Price
$13.86
$1.36
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$12.50
$5.75
AVG Volume (30 Days)
48.7K
23.6K
Earning Date
05-05-2026
03-26-2026
Dividend Yield
2.04%
N/A
EPS Growth
33.93
N/A
EPS
0.75
N/A
Revenue
$44,000.00
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
$7.25
N/A
P/E Ratio
$18.27
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.53
$1.18
52 Week High
$14.52
$2.63

Technical Indicators

Market Signals
Indicator
WNEB
IPHA
Relative Strength Index (RSI) 61.17 46.46
Support Level $12.07 $1.18
Resistance Level $14.06 $1.80
Average True Range (ATR) 0.30 0.08
MACD 0.00 -0.00
Stochastic Oscillator 69.07 23.26

Price Performance

Historical Comparison
WNEB
IPHA

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: